A PROSPECTIVE STUDY TO ASSESS THE TOXICITY PROFILE OF PACLITAXEL- CARBOPLATIN COMBINATION CHEMOTHERAPY IN ADVANCED NON SMALL CELL LUNG CANCER
Dr. Shiddalingesh Salimath and Dr. Praveen Kusbi*
ABSTRACT
Systemic chemotherapy is the accepted standard of care for advanced NSCLC. Presently Cisplatin-Etoposide combination chemotherapy is most commonly used regimen for advanced NSCLC. Of late Paclitaxel-carboplatin combination has emerged as an encouraging regimen, with overall improvement in quality of life and modest survival advantage. Therefore the present study is designed to evaluate the toxicity profile of Paclitaxel-carboplatin regimen in advanced NSCLC. Aims: To study the different types of toxicities seen in patients on Paclitaxel-carboplatin regimen, to assess the severity of toxicity by grading them according to the WORLD HEALTH ORGANISATION (WHO) toxicity grading. Patients and Methods: Fifty patients with chemotherapy-naive advanced NSCLC were enrolled between February 2008 and December 2009. Additional criteria included karnofsky performance status 60, and adequate organ function. Patients received Paclitaxel 175mg/sq m and Carboplatin AUC=6mg/ml min as intravenous infusion repeated every 21 days. Such 6 cycles were given. Results: The predominant toxicities were grade 1 myalgia(64%), Arthralgia(62%) and peripheral neuropathy(52%),.. Nausea was reported in (68%) and alopecia in (96%) of the cases among hematological toxicities, leucopoenia was present in (34%) of the patients. Conclusion: The most common toxicities observed were nausea, alopecia, arthralgia myalgia and peripheral neuropathy.
Keywords: Paclitaxel-carboplatin, Non-Small Cell Lung Cancer, Toxicity.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
